Mallinckrodt to acquire Stratatech

Monday, August 15, 2016

Mallinckrodt, a global specialty pharmaceutical company, has entered into a merger agreement with Stratatech, a privately held regenerative medicine company focused on the development of unique, proprietary skin substitute products. Developmental products include StrataGraft regenerative skin tissue and a technology platform for genetically enhanced skin tissues. Financial terms of the transaction were not disclosed.

[Read More]